PLEXXIKON AND ROCHE ENTER PARTNERSHIP TO DEVELOP TARGETED CANCER THERAPEUTIC MEDICINE PLX4032

Plexxikon Inc. and Roche announced they have entered into an agreement to develop and commercialize PLX4032, Plexxikon's investigational targeted cancer therapy which selectively inhibits B-RafV600E, a mutated form of the BRAF kinase gene. The BRAFV600E gene has been associated with increased tumor aggressiveness and decreased survival in many types of cancers and is a common cancer-causing kinase gene.
Pipeline Review